ONO 1714
Latest Information Update: 28 Oct 2003
Price :
$50 *
At a glance
- Originator Ono Pharmaceutical
- Class 2 ring heterocyclic compounds; Amidines; Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypotension; Shock; Type 1 diabetes mellitus
Most Recent Events
- 30 Sep 2002 Discontinued - Clinical-Phase-Unknown for Shock in United Kingdom (Injection)
- 30 Sep 2002 Discontinued - Phase-I for Hypotension in United Kingdom (Injection)
- 30 Sep 2002 Discontinued - Phase-II for Hypotension in Japan (Injection)